Eptifibatide pharmacology

Three intravenous GPIIb/llla inhibitors are currently available for clinical use abciximab, tirofiban, and eptifibatide (4-7). Their mechanisms of action, important differences in pharmacology as well as approved indications and dosing regimens are listed in Table I. [Pg.41]

Eptifibatide (Integrelin) [12,13] Cardiac Separate safety pharmacology studies One month (rat) One month (cyno) No Standard battery Synthetic FDA-1998 EMEA-1999... [Pg.503]

Eptifibatide. Summary Basis for Approval, Pharmacology Review, 1998. http // www.fda.gov/cder/foi/nda/98/20718 Integrilin.htm... [Pg.514]

Several natural and synthetic indole-containing cyclic peptides have pharmacological properties (Scheme 25). Daptomycin (167) was isolated from the soil microbe Streptomyces roseosporus and is used to treat gram-positive bacterial infections [150, 173]. The synthetic cyclic peptide eptifibatide (168) is a glycoprotein Ilb/IHa antagonist and platelet aggregation inhibitor. This drug is used to treat patients who have acute coronary syndrome (ACS) and are especially susceptible to blood clots [150,174]. [Pg.19]

Big Chemical Encyclopedia